share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外國發行人報告
美股SEC公告 ·  09/03 06:05
Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.
Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of a significant number of its securities. Specifically, 1,935,759,704 options, identified by the ASX security code ATHAAI and expiring on August 31, 2024, have ceased due to the expiry of the option without exercise or conversion. The cessation took place on August 31, 2024, and no consideration was paid by the entity for the cessation. Following this event, Alterity Therapeutics has updated its issued capital structure, which now comprises 5,320,336,118 ordinary fully paid shares and various classes of options with different expiry dates and exercise prices. The announcement was made on September 2, 2024, and is in accordance with the rules and regulations of the Securities Exchange Act of 1934. The company's issued capital information is crucial for investors as it affects the total market capitalization and share value.
Alterity Therapeutics Limited，一家發展階段的企業，宣佈終止了大量的證券。具體來說，標有ASX證券代碼ATHAAI，於2024年8月31日到期的1,935,759,704期權因未行使或轉換而終止。終止事件發生在2024年8月31日，實體對終止並未支付任何代價。在此事件後，Alterity Therapeutics已更新其已發行的資本結構，現擁有5,320,336,118普通全額支付股份和不同到期日期和行使價格的各類期權。該公告於2024年9月2日發佈，符合1934年證券交易法案的規定。公司的已發行資本信息對投資者至關重要，因爲它影響着總市值和股票價值。
Alterity Therapeutics Limited，一家發展階段的企業，宣佈終止了大量的證券。具體來說，標有ASX證券代碼ATHAAI，於2024年8月31日到期的1,935,759,704期權因未行使或轉換而終止。終止事件發生在2024年8月31日，實體對終止並未支付任何代價。在此事件後，Alterity Therapeutics已更新其已發行的資本結構，現擁有5,320,336,118普通全額支付股份和不同到期日期和行使價格的各類期權。該公告於2024年9月2日發佈，符合1934年證券交易法案的規定。公司的已發行資本信息對投資者至關重要，因爲它影響着總市值和股票價值。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息